Background: Psilocybe cubensis mushrooms contain the tryptamines psilocybin and psilocin, which are recognized for their therapeutic potential in mental health [1]. Additionally, due to their psychedelic effects, these mushrooms are also used for religious and recreational purposes. The increasing use of these tryptamines and other psychoactive substances ha...
-dimethyltryptamine (DMT) biosynthetic pathway in hallucinogenic plant species traditionally used in shamanic rituals for spiritual healing. Leveraging the similarities in their chemical structures, we reconstructed in one plant assay the full biosynthetic pathways of five renowned natural psychedelics; psilocin and psilocybin found in mushrooms, DMT from pl...
The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin: 1. Changes connectivity within brain networks associated with mood...
Background/Objectives: Psilocybin has re-emerged as a promising intervention for neuropsychiatric disorders including major depressive disorder, treatment-resistant depression, anxiety associated with life-threatening illness, obsessive compulsive disorder, and substance use disorders. However, conventional randomized controlled trials (RCTs)-the current gol...
While the limitations of existing treatment options have spurred investigations into the applicability of psychedelic therapies for chronic and treatment-resistant psychological disorders, there remain significant unresolved issues pertaining to how these treatments should be regulated and the implementation of an ethical framework for their widespread deliv...
Nach einer Pause gibt es heute wieder Evidenz-Quickies, und zwar gleich mehrere, dafür aber kürzer und weniger ausführlich als zuletzt. Und dieses Format ist jetzt zweigeteilt: (a) Für alle, denen die Nachricht genügt, gibt es oben die Quickies in Kürze. (b) Alle, die weiterlesen wollen, finden die detaillierten Fassungen unten. Viel Freude und hoffentlich i...
Depression and psychological distress are highly prevalent among patients with cancer and are associated with impaired quality of life, reduced treatment adherence, and poorer clinical outcomes. Standard pharmacological and psychosocial interventions often demonstrate limited efficacy or delayed onset of action in oncological and palliative settings. Psilocy...
In April 2024, FSQ Forensic Chemists attended Queensland’s largest mushroom growing operation. Seized items included: 219 50 L plastic tubs of mushrooms in growth medium, bags of dried mushroom material, sterilised grain bags and spores in liquid. In consultation with QPS, six exhibits were selected for illicit drug analysis. Fresh mushrooms were harvested a...
Introduction This computational modeling study introduces a novel Explainable Artificial Intelligence (XAI) framework for optimizing single-dose psilocybin treatment protocols through personalized intervention modeling using publicly available mental health datasets. All results presented are derived from novel simulated data and predictive modeling only, no...
The psychedelic mushroom Psilocybe cubensis is cultivated worldwide for recreational and medicinal use. Described initially from Cuba in 1906, there has been substantial debate about its origin and diversification. The prevailing view is that P. cubensis was inadvertently introduced to the Americas when cattle were introduced to the continent from Africa and...
Psilocybin is an emerging investigational compound with therapeutic potential in neuropsychiatric disorders, creating a need for flexible and scalable dosage forms suitable for early clinical development. This study aimed to develop and evaluate psilocybin-loaded oral thin film (OTF) formulations as a dose-proportional platform for early-phase clinical use. ...
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for mood and anxiety disorders, the same conditions under which psychedelic-assisted therapies are gaining renewed interest. However, it remains unclear how SSRI treatment may influence sensitivity to psychedelics, particularly through the shared engagement of serotonergic pathways. Here, ...
To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), along with putative minor metabolites and several deuterium-labeled derivatives. Psilocybin, psilocin, psilocin-O-glucuronide, and 4-HIAA were assayed for engage...
Support for the legal use of psilocybin mushrooms (23%) is much lower than it is for cannabis (65%), according to a new RAND research report, released Feb. 24. For LSD and 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy, support for legal use is closer to 10%.
This paper follows 8 scientists who ventured into the world of psychedelics on a quest to find transformational pathways forward. Each have worked on aspects of global environmental change for decades, and observing environmental crises converging into a global polycrisis/metacrisis with genuine potential for collapse, we have all carried psychological burde...
Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review provides a comprehensive overview of psilocybin's history, recent clinical evidence, ongoing clinical trials, neuroimaging findings, and regulations. Historically used in spiritual and healing rituals, psilocybin w...
ABSTRACT This paper examines the intimate relationship of affection, consumption, and ritual practice between humanity and mushrooms of the genus Psilocybe, focusing mainly on the Americas and Brazil. To this end, it uses reflections that present the American continent as a macroregion historically marked by transits, connections, and exchanges since pre-Col...
